Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 2,500 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 2,500 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $7.82, for a total transaction of $19,550.00. Following the sale, the chief executive officer now owns 120,695 shares of the company’s stock, valued at $943,834.90. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

Richard Nolan Townsend also recently made the following trade(s):

• On Thursday, October 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $8.10, for a total transaction of $40,500.00.
• On Tuesday, September 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $10.65, for a total value of $53,250.00.

Lexeo Therapeutics Stock Down 0.7 %

Shares of NASDAQ LXEO traded down $0.05 during trading hours on Wednesday, hitting $7.64. 5,966,935 shares of the stock were exchanged, compared to its average volume of 244,379. The firm has a fifty day moving average price of $9.24 and a 200-day moving average price of $12.33. The company has a quick ratio of 9.38, a current ratio of 9.38 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics, Inc. has a 12 month low of $7.47 and a 12 month high of $22.33. The company has a market cap of $252.58 million and a PE ratio of -0.52.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.64) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.64). On average, sell-side analysts expect that Lexeo Therapeutics, Inc. will post -2.76 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on LXEO. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of Lexeo Therapeutics in a research report on Thursday, October 31st. Chardan Capital boosted their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Finally, Leerink Partners cut their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $22.43.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new stake in shares of Lexeo Therapeutics during the first quarter worth about $75,000. Vanguard Group Inc. raised its holdings in Lexeo Therapeutics by 15.8% during the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock worth $7,554,000 after purchasing an additional 65,573 shares in the last quarter. American International Group Inc. acquired a new stake in shares of Lexeo Therapeutics during the first quarter worth about $79,000. Janus Henderson Group PLC lifted its stake in Lexeo Therapeutics by 9.0% in the first quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock valued at $39,802,000 after buying an additional 210,047 shares during the last quarter. Finally, Artal Group S.A. grew its position in Lexeo Therapeutics by 32.9% during the 1st quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock worth $12,571,000 after purchasing an additional 198,281 shares during the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.